Home Cart Sign in  
Chemical Structure| 1306760-87-1 Chemical Structure| 1306760-87-1

Structure of Ozanimod
CAS No.: 1306760-87-1

Chemical Structure| 1306760-87-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Ozanimod is an oral, once daily, selective sphingosine 1-phosphate 1 and 5 receptor modulator in development for autoimmune indications including relapsing multiple sclerosis (RMS) and ulcerative colitis (UC).

Synonyms: RPC-1063

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Yang, Jingdong ; Qian, Yuanyuan ; Kim, Choon ; Birhanu, Biruk T ; Cal y Mayor-Luna, Carlos ; Ding, Derong , et al.

Abstract: Clostridioides difficile, a Gram-positive, spore-forming anaerobic bacterium, is a major healthcare threat. Its spores colonize the gut following dysbiosis caused by broad-spectrum antibiotics, remaining dormant until host’s bile acid triggers germination into vegetative cells that produce toxins, leading to diarrhea, colitis, and potentially death. Current antibiotics to treat C. difficile infection target vegetative cells but not spore germination, a pivotal step in infection development. This study unveils 1,2,4-oxadiazoles as a novel class of spore germination inhibitors and delineates the structure−activity relationship. Screening of 120 oxadiazoles revealed compound 110 (IC50 = 14 ± 1 μM or 6.3 ± 0.4 μg/mL). Compound 110 targets mature SleC (Kd = 12 ± 1.0 μM) and CspB (Kd = 8.0 ± 1.0 μM) on spores, inhibiting their enzymatic activities, thus preventing spore germination. To our knowledge, compound 110 is the first reported spore germination inhibitor targeting SleC/CspB, offering a promising avenue for C. difficile therapies.

Purchased from AmBeed: ;

Alternative Products

Product Details of Ozanimod

CAS No. :1306760-87-1
Formula : C23H24N4O3
M.W : 404.46
SMILES Code : N#CC1=CC(C2=NC(C3=CC=CC4=C3CC[C@@H]4NCCO)=NO2)=CC=C1OC(C)C
Synonyms :
RPC-1063
MDL No. :MFCD28386168
InChI Key :XRVDGNKRPOAQTN-FQEVSTJZSA-N
Pubchem ID :52938427

Safety of Ozanimod

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Ozanimod

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
BV2 cells 1000 nM 2 hours SR9011 inhibited LPS-induced iNOS and COX-2 protein expression PMC7291065
HEK293T cells 1 μM 1 hour To evaluate the effect of ACBI1 on SMARCA4 protein levels in HEK293T cells, results showed that ACBI1 treatment led to a reduction in SMARCA4 protein levels. PMC4867749

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Experimental autoimmune encephalitis (EAE) model Oral 0.2 and 0.6 mg/kg Once daily for 14 days To evaluate the therapeutic effects of Ozanimod in the EAE model, results showed that Ozanimod dose-dependently reduced disease scores and weight loss. PMC4867749
C57BL/6 female mice Experimental autoimmune encephalomyelitis (EAE) Oral 0.6mg/kg Daily administration for 21 days Ozanimod treatment significantly improved clinical symptoms in EAE mice, reduced the percentage of autoreactive CD4+ and CD8+ T cells, and significantly inhibited lymphocyte infiltration into the spinal cord, accompanied by reversed demyelination. Furthermore, ozanimod treatment resulted in a significant increase in the frequency of total NK cells in the blood and CNS along with upregulation of the activating receptor NKG2D on CD27low/- NK cell subset in the CNS. The effectiveness of ozanimod treatment in inhibiting the progression of the disease was reduced when NK cells were depleted using anti-NK1.1 mAb. PMC10963535
CX3CR1-GFP transgenic mice Light-induced photoreceptor loss model (LI-PRL) Oral gavage 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, and 5 mg/kg body weight Daily administration for 5 or 6 weeks To assess the neuroprotective effects of RP-101074 in a non-inflammatory neurodegenerative disease model. Results showed that prophylactic administration of RP-101074 demonstrated protective effects following a bell-shaped dose-response curve, with beneficial outcomes on retinal layer thickness and visual function. PMC10450045
Mice Cerebrovascular thrombosis model Intravenous injection 0.6 mg/kg Single dose, observed for 90 minutes To evaluate the effects of Ozanimod combined with low-dose tPA on microvascular hemodynamics following cerebrovascular thrombosis. Results showed that Ozanimod significantly restored flow velocity after thrombosis, reduced thrombus volume, and did not affect coagulation and bleeding time. PMC9198651
C57BL/6 female mice Experimental Autoimmune Encephalomyelitis (EAE) Intracerebroventricular (icv) 2.7 µg/day and 0.55 µg/day Continuous for 4 weeks AUY954 treatment ameliorated EAE clinical score without affecting peripheral T cell counts PMC7291065

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT04211558 Healthy Volunteer PHASE1 COMPLETED 2020-10-09 Capital Medical University - B... More >>eijing Anzhen Hospital, Beijing, 100029, China Less <<
NCT05076175 Colitis, Ulcerative PHASE2|PHASE3 RECRUITING 2031-08-14 Local Institution - 0041, Phoe... More >>nix, Arizona, 85016-7710, United States|University of Arizona, Tucson, Arizona, 85724, United States|Local Institution - 0052, Garden Grove, California, 92845, United States|Loma Linda University Health System, Loma Linda, California, 92354, United States|Cedars-Sinai Medical Center, Los Angeles, California, 90048, United States|Lucile Packard Children's Hospital, Palo Alto, California, 94304, United States|Local Institution - 0096, Sacramento, California, 95817, United States|Local Institution - 0007, Hartford, Connecticut, 06106, United States|Children's National Medical Center, Washington, District of Columbia, 20010, United States|Local Institution - 0075, Orlando, Florida, 32803, United States|Local Institution - 0016, Atlanta, Georgia, 30342, United States|University of Iowa, Iowa City, Iowa, 52242, United States|Maine Medical Partners, Portland, Maine, 04102, United States|Boston Children's Hospital, Boston, Massachusetts, 02115, United States|Local Institution - 0042, Springfield, Massachusetts, 01199, United States|University of Massachusetts Chan Medical School, Worcester, Massachusetts, 01655, United States|Children's Hospital of Michigan, Detroit, Michigan, 48201, United States|Mayo Clinic in Rochester, Minnesota, Rochester, Minnesota, 55905, United States|Washington University, Saint Louis, Missouri, 63110, United States|Local Institution - 0028, New York, New York, 10029, United States|Columbia University Medical Center, New York, New York, 10032, United States|Local Institution - 0023, New York, New York, 10065, United States|University of North Carolina Medical Center, Chapel Hill, North Carolina, 27599, United States|Local Institution - 0047, Charlotte, North Carolina, 28203, United States|Cleveland Clinic, Cleveland, Ohio, 44124, United States|Local Institution - 0062, Oklahoma City, Oklahoma, 73112, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, 17033, United States|Texas Children's Hospital, Houston, Texas, 77030, United States|Seattle Children's Hospital, Seattle, Washington, 98105, United States|Swedish Medical Center, Seattle, Washington, 98122, United States|MultiCare Health System, Tacoma, Washington, 98405, United States|Children's Wisconsin, Milwaukee, Wisconsin, 53226, United States|Local Institution - 0094, Westmead, New South Wales, 2145, Australia|Monash Health, Clayton, Victoria, 3168, Australia|Local Institution - 0086, Murdoch, Western Australia, 6150, Australia|Local Institution - 0076, Brussels, Bruxelles-Capitale, Région De, 1090, Belgium|Local Institution - 0059, Leuven, Vlaams-Brabant, 3000, Belgium|Local Institution - 0056, Brussels, 1090, Belgium|Local Institution - 0063, Edegem, 2650, Belgium|Local Institution - 0061, Liège, 4000, Belgium|Local Institution - 0071, Liège, 4000, Belgium|Local Institution - 0083, Hamilton, Ontario, L8N 3Z5, Canada|Local Institution - 0082, Toronto, Ontario, M5G 1X8, Canada|CHU de Toulouse - H?pital des Enfants, Toulouse, Haute-Garonne, 31059, France|Hospices Civils de Lyon - H?pital Femme Mère Enfant, Bron, 69500, France|Centre Hospitalier Universitaire de Caen - H?pital C?te de Nacre, Caen, 14033, France|H?pital Universitaire Necker Enfants Malades, Paris, 75015, France|Local Institution - 0073, Paris, 75571, France|Klinikum der Ludwig-Maximilians-Universitaet Muenchen, München, Bayern, 80337, Germany|Local Institution - 0097, Leipzig, Sachsen, 04103, Germany|Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, 01307, Germany|Schneider Children's Medical Center, Petah-Tikva, HaMerkaz, 49202, Israel|Rambam Health Care Campus, Haifa, HaTsafon, 3109601, Israel|Local Institution - 0019, Jerusalem, Yerushalayim, 9013102, Israel|Local Institution - 0025, Obu, Aichi, 474-8710, Japan|Local Institution - 0011, Kurume-shi, Fukuoka, 8300011, Japan|Local Institution - 0068, Komatsu, Ishikawa, 923-8560, Japan|Local Institution - 0038, Yokohama-shi, Kanagawa, 2300012, Japan|Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Osaka, 569-8686, Japan|Tokyo Medical and Dental University Hospital, Bunkyo-ku, Tokyo, 1138519, Japan|National Center for Child Health and Development, Setagaya-ku, Tokyo, 1578535, Japan|Local Institution - 0033, Shinjuku-ku, Tokyo, 160-0023, Japan|Hiroshima University Hospital, Hiroshima, 7348551, Japan|Local Institution - 0010, Tokyo, 113-8431, Japan|Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroc?awiu, Wroc?aw, Dolno?l?skie, 50-369, Poland|Local Institution - 0043, Warsaw, Mazowieckie, 00-728, Poland|Centrum Zdrowia Dziecka w Warszawie, Warsaw, Mazowieckie, 04-746, Poland|Local Institution - 0084, Krakow, Ma?opolskie, 30-663, Poland|Local Institution - 0015, Rzeszów, Podkarpackie, 35-302, Poland|Local Institution - 0013, Gdansk, Pomorskie, 80-803, Poland|Local Institution - 0079, Gdansk, Pomorskie, 80-803, Poland|Twoja Przychodnia SCM, Szczecin, Zachodniopomorskie, 71-434, Poland|Local Institution - 0092, Lodz, ?ódzkie, 91-738, Poland|Local Institution, Moscow, 119991, Russian Federation|Local Institution, Moskva, 119571, Russian Federation|Local Institution - 0048, Badalona, Barcelona [Barcelona], 08916, Spain|Local Institution - 0051, Esplugues de Llobregat, Barcelona [Barcelona], 08950, Spain|Local Institution - 0044, Madrid, Madrid, Comunidad De, 28009, Spain|Hospital General Universitario Gregorio Mara?on, Madrid, 28007, Spain|Local Institution - 0050, Madrid, 28046, Spain|Local Institution - 0054, Birmingham, England, B4 6NH, United Kingdom|King's College Hospital, London, Greater London, SE5 9RS, United Kingdom|Local Institution - 0066, London, London, City Of, E1 1BB, United Kingdom Less <<
NCT06529406 Relapsing Multiple Sclerosis PHASE4 RECRUITING 2029-08-01 University of Colorado Anschut... More >>z Medical Campus, Aurora, Colorado, 80045, United States|Cleveland Clinic, Las Vegas, Nevada, 89106, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States Less <<
NCT06334094 Multiple Sclerosis PHASE4 WITHDRAWN 2028-05-31 Center for Brain Health, Dalla... More >>s, Texas, 75228, United States Less <<
NCT05001152 Healthy Volunteers PHASE1 COMPLETED 2021-09-27 Local Institution - 0001, Wobu... More >>rn, Massachusetts, 01801-6353, United States|Senopsys LLC, Woburn, Massachusetts, 01801, United States Less <<
NCT04639115 Liver Diseases|Digestive Syste... More >>m Diseases Less << PHASE1 COMPLETED 2022-04-06 University of Miami Miller Sch... More >>ool of Medicine, Miami, Florida, 33136, United States|Orlando Clinical Research Center OCRC, Orlando, Florida, 32809, United States|The Texas Liver Institute, San Antonio, Texas, 78215, United States Less <<
NCT05809583 Ulcerative Colitis NOT_YET_RECRUITING 2024-04-01 Beth Israel Deaconess Medical ... More >>Center, Boston, Massachusetts, 02215, United States Less <<
NCT05319093 Fatigue|Multiple Sclerosis UNKNOWN 2025-12-23 -
NCT06073873 Ulcerative Colitis RECRUITING 2028-04-01 Bristol-Myers Squibb YH, Seoul... More >>, 06178, Korea, Republic of Less <<
NCT05369832 Colitis, Ulcerative PHASE4 ACTIVE_NOT_RECRUITING 2025-04-15 Local Institution - 0048, Doth... More >>an, Alabama, 36305-1156, United States|Local Institution - 0206, Chandler, Arizona, 85224-1636, United States|Local Institution - 0216, Gilbert, Arizona, 85297-0425, United States|Local Institution - 0125, Sun City, Arizona, 85351-2867, United States|Local Institution - 0195, Tucson, Arizona, 85724-0001, United States|Local Institution - 0045, North Little Rock, Arkansas, 72117-2927, United States|Local Institution - 0165, Apple Valley, California, 92307-1329, United States|Local Institution - 0162, Camarillo, California, 93012-5156, United States|Local Institution - 0014, Lancaster, California, 93534-5856, United States|OM Research LLC - Lancaster - ClinEdge - PPDS, Lancaster, California, 93534-5856, United States|Local Institution - 0209, Los Angeles, California, 90045-3119, United States|Local Institution - 0002, San Diego, California, 92103-5639, United States|Local Institution - 0208, San Diego, California, 92123-4207, United States|Local Institution - 0185, San Jose, California, 95116, United States|Local Institution - 0178, Littleton, Colorado, 80120-5641, United States|Gastro Florida, Clearwater, Florida, 33756-3839, United States|Local Institution - 0018, Clearwater, Florida, 33756-3839, United States|Local Institution - 0050, Homestead, Florida, 33033, United States|Local Institution - 0026, Lighthouse Point, Florida, 33064-7058, United States|Local Institution - 0049, Miami Lakes, Florida, 33016-5861, United States|Wellness Clinical Research-Miami Florida, Miami Lakes, Florida, 33016-5861, United States|Local Institution - 0167, Miami, Florida, 33136-1002, United States|Gastroenterology Group of Naples, Naples, Florida, 34102-5449, United States|Local Institution - 0003, Naples, Florida, 34102-5449, United States|Local Institution - 0058, Orange Park, Florida, 32073-4752, United States|Local Institution - 0205, Orlando, Florida, 32806-1110, United States|Local Institution - 0037, Palm Harbor, Florida, 34684, United States|Local Institution - 0179, Wellington, Florida, 33414-3187, United States|Local Institution - 0027, Roswell, Georgia, 30076-4969, United States|Local Institution - 0198, Arlington Heights, Illinois, 60005, United States|Local Institution - 0051, Chicago, Illinois, 60611, United States|Local Institution - 0098, Gurnee, Illinois, 60031, United States|Local Institution - 0192, Kansas City, Kansas, 66160-8500, United States|Local Institution - 0181, Topeka, Kansas, 66606-1539, United States|Local Institution - 0183, Louisville, Kentucky, 40202, United States|Local Institution - 0200, Baton Rouge, Louisiana, 70809-2440, United States|Local Institution - 0171, Chevy Chase, Maryland, 20815-7313, United States|Local Institution - 0191, Glen Burnie, Maryland, 21061-9121, United States|Local Institution - 0199, Boston, Massachusetts, 02111, United States|Local Institution - 0196, Worcester, Massachusetts, 01655, United States|Local Institution - 0174, Plymouth, Minnesota, 55446-3661, United States|Local Institution - 0184, Ocean Springs, Mississippi, 39564-5803, United States|Local Institution - 0024, Chesterfield, Missouri, 63005-1248, United States|Local Institution - 0213, Weldon Spring, Missouri, 63304-9103, United States|Local Institution - 0180, Englewood, New Jersey, 07631-4141, United States|Local Institution - 0084, Brooklyn, New York, 11203-2054, United States|Local Institution - 0187, New York, New York, 10016-6821, United States|Local Institution - 0059, New York, New York, 10016-9401, United States|NYU Langone Health -Inflammatory Bowel Disease Center, New York, New York, 10016-9401, United States|Local Institution - 0176, New York, New York, 10021, United States|Local Institution - 0170, Utica, New York, 13502, United States|Carolina Digestive Diseases, Greenville, North Carolina, 27834-3761, United States|Local Institution - 0005, Cincinnati, Ohio, 45229-3019, United States|University of Cincinnati Physicians Company, Cincinnati, Ohio, 45229-3019, United States|Local Institution - 0188, Columbus, Ohio, 43235-5424, United States|Local Institution - 0061, Mentor, Ohio, 44060-6521, United States|Local Institution - 0060, Providence, Rhode Island, 02905-3105, United States|Local Institution - 0177, Cordova, Tennessee, 38018-6362, United States|Local Institution - 0168, Nashville, Tennessee, 37211-4981, United States|Local Institution - 0038, Bellaire, Texas, 77401, United States|Novel Research LLC, Bellaire, Texas, 77401, United States|Local Institution - 0138, Dallas, Texas, 75246, United States|Local Institution - 0036, Houston, Texas, 77024-2469, United States|Local Institution - 0163, Houston, Texas, 77024-2469, United States|Ace Clinical Research Group: Digestive Health Associates, Houston, Texas, 77024, United States|Houston Methodist Hospital, Houston, Texas, 77030, United States|Local Institution - 0052, Houston, Texas, 77030, United States|Local Institution - 0129, Katy, Texas, 77494, United States|Local Institution - 0161, Lubbock, Texas, 79410-2014, United States|GI Alliance: Mansfield - TDDC, Mansfield, Texas, 76063-6083, United States|Local Institution - 0039, Mansfield, Texas, 76063-6083, United States|Local Institution - 0201, San Antonio, Texas, 78229-3270, United States|Local Institution - 0043, San Antonio, Texas, 78229-4463, United States|San Antonio Gastroenterology, San Antonio, Texas, 78229-4463, United States|Local Institution - 0166, San Marcos, Texas, 78666-7502, United States|Local Institution - 0046, Tyler, Texas, 75701-4464, United States|Tyler Research Institute, LLC, Tyler, Texas, 75701-4464, United States|Local Institution - 0091, Webster, Texas, 77598, United States|Local Institution - 0193, Ogden, Utah, 84403-3294, United States|Local Institution - 0169, Salt Lake City, Utah, 84132-0001, United States|Local Institution - 0197, Lynchburg, Virginia, 24502, United States|Local Institution - 0130, Seattle, Washington, 98104-1356, United States|Local Institution - 0189, Tacoma, Washington, 98405-2318, United States|Local Institution - 0017, Madison, Wisconsin, 53705-1311, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, 53792, United States Less <<
NCT04140305 Multiple Sclerosis PHASE3 ACTIVE_NOT_RECRUITING 2026-04-27 Local Institution - 123, Birmi... More >>ngham, Alabama, 35209, United States|Local Institution - 136, Cullman, Alabama, 35058, United States|Local Institution - 153, Mobile, Alabama, 36617, United States|Local Institution - 162, Phoenix, Arizona, 85018, United States|Local Institution - 128, Pasadena, California, 91105, United States|Local Institution - 164, Sacramento, California, 95817, United States|Local Institution - 107, Aurora, Colorado, 80045, United States|Local Institution - 102, Colorado Springs, Colorado, 80907, United States|Local Institution - 144, Fort Collins, Colorado, 80528, United States|Local Institution - 109, Washington, District of Columbia, 20007, United States|Local Institution - 140, Boca Raton, Florida, 33428, United States|Local Institution - 158, Vero Beach, Florida, 32960-4818, United States|Local Institution - 114, Savannah, Georgia, 31406, United States|Northwest Neurology, Ltd, Hoffman Estates, Illinois, 60169, United States|Local Institution - 108, Northbrook, Illinois, 60062, United States|Local Institution - 148, Fort Wayne, Indiana, 46825-1603, United States|Local Institution - 126, Ames, Iowa, 50010, United States|Local Institution - 173, Kansas City, Kansas, 66160, United States|Local Institution - 133, Alexandria, Louisiana, 71301, United States|Local Institution - 152, Detroit, Michigan, 48201, United States|Local Institution - 112, Detroit, Michigan, 48202, United States|Local Institution - 122, Saint Louis, Missouri, 63110, United States|Local Institution - 143, Saint Louis, Missouri, 63131, United States|Advanced Neurology Specialists, Great Falls, Montana, 59405, United States|Local Institution - 149, Teaneck, New Jersey, 07666, United States|Dent Neurologic Institute, Amherst, New York, 14226, United States|Local Institution - 137, Buffalo, New York, 14202, United States|Local Institution - 160, East Setauket, New York, 11733-3528, United States|Local Institution - 130, New York, New York, 10016, United States|Local Institution - 121, New York, New York, 10021, United States|Local Institution - 146, Patchogue, New York, 11772, United States|Local Institution - 131, Chapel Hill, North Carolina, 27514, United States|Local Institution - 106, Greensboro, North Carolina, 27405, United States|Local Institution - 170, Mooresville, North Carolina, 28117, United States|Raleigh Neurology Associates PA, Raleigh, North Carolina, 27607, United States|Local Institution - 174, Cincinnati, Ohio, 45219, United States|Local Institution - 171, Cleveland, Ohio, 44106, United States|UC Health, LLC, Dayton, Ohio, 45417, United States|Local Institution - 157, Oklahoma City, Oklahoma, 73104, United States|Local Institution - 159, Philadelphia, Pennsylvania, 19107, United States|Local Institution - 169, Philadelphia, Pennsylvania, 19140, United States|University of Pittsburgh Medical Center Magee Womens Hospital, Pittsburgh, Pennsylvania, 15213, United States|Local Institution - 125, Franklin, Tennessee, 37064, United States|Local Institution - 119, Knoxville, Tennessee, 37922, United States|Local Institution - 139, Dallas, Texas, 75246, United States|Local Institution - 113, Round Rock, Texas, 78681, United States|Local Institution - 101, San Antonio, Texas, 78259, United States|Local Institution - 103, Norfolk, Virginia, 23502, United States|Local Institution - 141, Kirkland, Washington, 98034, United States|Local Institution - 168, Seattle, Washington, 98101, United States|Local Institution - 172, Spokane, Washington, 99202, United States|Local Institution - 124, Tacoma, Washington, 98405, United States|Local Institution - 156, Huntington, West Virginia, 25701, United States|Local Institution - 150, Morgantown, West Virginia, 26506, United States|Local Institution - 167, Madison, Wisconsin, 53792, United States|Local Institution - 147, Milwaukee, Wisconsin, 53226, United States|Local Institution - 203, London, Ontario, N6G 2V4, Canada|Local Institution - 204, Ottawa, Ontario, K1H 8L6, Canada|Local Institution - 206, Montreal, Quebec, H2X 0A9, Canada|Local Institution - 207, Halifax, B3R 1V9, Canada|Local Institution - 166, Guaynabo, 00968, Puerto Rico Less <<
NCT05470985 Crohn Disease PHASE2|PHASE3 COMPLETED 2024-09-13 Local Institution - 0010, Gard... More >>en Grove, California, 92845-2032, United States|Local Institution - 0028, Los Angeles, California, 90027-6062, United States|Local Institution - 0002, Sacramento, California, 95817-2207, United States|Local Institution - 0009, San Francisco, California, 94158, United States|Local Institution - 0011, Hartford, Connecticut, 06106-3322, United States|Local Institution - 0044, Orlando, Florida, 32803-1469, United States|Local Institution - 0037, Orlando, Florida, 32806, United States|Local Institution - 0053, Atlanta, Georgia, 30302, United States|Local Institution - 0059, Indianapolis, Indiana, 46202-5109, United States|Local Institution - 0038, Springfield, Massachusetts, 01199, United States|Local Institution - 0006, Detroit, Michigan, 48201-2196, United States|Local Institution - 0003, Rochester, Minnesota, 55905-0001, United States|Local Institution - 0016, Saint Louis, Missouri, 63110-1002, United States|Local Institution - 0071, Lebanon, New Hampshire, 03756-1000, United States|Local Institution - 0060, New York, New York, 10032, United States|Local Institution - 0075, Fort Worth, Texas, 76104-2710, United States|Local Institution - 0070, Houston, Texas, 77030-2316, United States|Local Institution - 0008, Seattle, Washington, 98105-3901, United States|Local Institution - 0040, Tacoma, Washington, 98405-3720, United States|Local Institution - 0045, Joonladup, Western Australia, 6027, Australia|Local Institution - 0058, Brussel, BRU, 1020, Belgium|Local Institution - 0023, Leuven, VBR, 3000, Belgium|Local Institution - 0062, Liege, WLG, 4000, Belgium|Local Institution - 0048, Liège, WLG, 4000, Belgium|Local Institution - 0047, Brussel, 1090, Belgium|Local Institution - 0055, Bruxelles, 1200, Belgium|Local Institution - 0014, Halifax, Nova Scotia, B3K 6R8, Canada|Local Institution - 0001, London, Ontario, N6A 5W9, Canada|Local Institution - 0054, Montreal, Quebec, H3T 1C5, Canada|Local Institution - 0066, Bron, 69500, France|Local Institution - 0065, Caen, 14033, France|Local Institution - 0072, Paris, 75015, France|Local Institution - 0063, Toulouse, 31059, France|Local Institution - 0057, Dresden, SN, 01307, Germany|Local Institution - 0067, Leipzig, SN, 04103, Germany|Local Institution - 0015, Miskolc, 3526, Hungary|Local Institution - 0026, Szeged, 6720, Hungary|Local Institution - 0007, Warszawa, MZ, 00-728, Poland|Local Institution - 0052, Rzeszow, PK, 35-302, Poland|Local Institution - 0061, Lodz, 91-738, Poland|Local Institution - 0033, Warsaw, 04-746, Poland|Local Institution - 0031, Warszawa, 00-635, Poland|Local Institution - 0025, Barcelona, B, 8950, Spain|Local Institution - 0030, Badalona, 08916, Spain|Local Institution - 0035, Barcelone, 08035, Spain|Local Institution - 0017, Madrid, 28009, Spain Less <<
NCT05382715 Colitis, Ulcerative RECRUITING 2026-11-30 Local Institution - 0001, Berl... More >>in, 10825, Germany Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.47mL

0.49mL

0.25mL

12.36mL

2.47mL

1.24mL

24.72mL

4.94mL

2.47mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories